Name
Mixed cellularity classic Hodgkin lymphoma
ICD-O-1 Morphology
9652/3: Hodgkin lymphoma, mixed cellularity, NOS
Effective
1978 - 1991
ICD-O-2 Morphology
9652/3: Hodgkin lymphoma, mixed cellularity, NOS
Effective
1992 - 2000
ICD-O-3 Morphology
9652/3: Hodgkin lymphoma, mixed cellularity, NOS
Effective
2001 and later
Reportable
for cases diagnosed
1978 and later
Primary Site(s)
C770-C779
Lymph nodes (C770-C779) are the usual primary sites; however, involvement in other sites is possible. If you have confirmation that the only involved site is something other than the lymph nodes, then code to that primary site. See Module 7.
Coding Manual:
Hematopoietic Coding Manual (PDF)
Abstractor Notes
Mixed cellularity classical Hodgkin lymphoma (MCCHL) frequently involves peripheral lymph nodes. Mediastinal involvement is uncommon. The spleen is involved in 30%, bone marrow in 10%, liver in 3%, and other organs in 1-3%. MCCHL is more frequent in patients with HIV infection and in developing countries.
With current regimens, MCCHL has approximately the same prognosis as nodular sclerosis and a better prognosis than lymphocyte-depleted CHL.
With current regimens, MCCHL has approximately the same prognosis as nodular sclerosis and a better prognosis than lymphocyte-depleted CHL.
Diagnostic Confirmation
This histology can be determined by positive histology (including peripheral blood) with or without genetics and/or immunophenotyping. Review the Definitive Diagnostic Methods, Immunophenotyping and Genetics Data sections below, and the instructions in the Hematopoietic Manual for further guidance on assigning Diagnostic confirmation.
Grade
Not Applicable
Module Rule
None
Alternate Names
Classical Hodgkin lymphoma, mixed cellularity, NOS
Hodgkin lymphoma, mixed cellularity, NOS
MCCHL
MC-HL
Definition
Mixed cellularity classic Hodgkin lymphoma (MCCHL) is a subtype of classic Hodgkin lymphoma (CHL) characterized by classic Hodgkin/Reed-Sternberg (HRS) cells in a diffuse mixed inflammatory background. Fine interstitial fibrosis may be present, but fibrous brands are absent and capsular fibrosis is usually absent.
Definitive Diagnostic Methods
Histologic confirmation
Immunophenotyping
Genetics Data
None
Immunophenotyping
EBV-encoded small RNA (EBER)
EBV-encoded LMP1
Treatments
Chemotherapy
Hormone therapy
Radiation therapy
Transformations to
None
Transformations from
Same Primaries
Corresponding ICD-9 Codes
201.6 Hodgkin's disease, mixed cellularity
Corresponding ICD-10 Codes
C81.2 Hodgkin mixed cellularity
Corresponding ICD-10-CM Codes (U.S. only)
C81.2 Mixed cellularity Hodgkin lymphoma (effective October 01, 2015)
Signs and Symptoms
Drenching night sweats
Fatigue
Fever (for no known reason)
Painless swelling in the lymph nodes
Peripheral lymphadenopathy
Skin rash or itchy skin
Weight loss (for no known reason)
Diagnostic Exams
Progression and Transformation
None
Epidemiology and Mortality
Sources
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (Eds):
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Hodgkin lymphomas
Pages: 440
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Revised 4th edition)
IARC: Lyon 2017
Section: Hodgkin lymphomas
Pages: 440
International Classification of Diseases for Oncology, Third Edition, Second Revision. Geneva: World Health Organization, 2020.
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
Section: ICD-O-3.2 (2020) Morphological Codes
Pages: http://www.iacr.com.fr/index.php?option=com_content&view=category&layout=blog&id=100&Itemid=577
National Cancer Institute
Section: General Information About Adult Hodgkin Lymphoma (HL)
Pages: https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq
Section: General Information About Adult Hodgkin Lymphoma (HL)
Pages: https://www.cancer.gov/types/lymphoma/hp/adult-hodgkin-treatment-pdq